Drug Stocks In Focus (SNSS, ARNA, MDT, PFE)

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) soared 13.20% to $0.440. RBC Capital upgraded Sunesis Pharmaceuticals Inc. to an Outperform rating from its previous rating of Sector Perform. The firm is also lowering its price target to $1 from $2.

The company has Price/Book ratio of 2.62. The stock has the 50- Day Moving Average and 200-Day Moving Average prices of $0.35 and $0.43 respectively. At current market price, the market capitalization of the company stands at $117.02 million.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) jumped 10.91% to $1.83. Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

At current market price, the market capitalization of the company stands at $222.18 million. The stock is down more than 48% year-to-date.

Medtronic, Inc. (NYSE:MDT) added 1.47% to $37.95. The company announced that William A. Hawkins intends to retire as Chairman and Chief Executive Officer of Medtronic at the conclusion of the current fiscal year ending April 29, 2011. 

The company has Price/Sales ratio of 2.57. The stock has the 50- Day Moving Average and 200-Day Moving Average prices of $34.98 and $35.41 respectively. At current market price, the market capitalization of the company stands at $40.74 billion.